IntelGenx Technologies Corp. (IGX.TO) TSX
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
IntelGenx Technologies Corp.
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
May 27, 2008
Key Executives
| Name | Title | Pay | Year Born |
| Dwight Gorham | Chief Executive Officer & Director | 316,887 | 1958 |
| Tommy Kenny | Senior Vice President & General Counsel | 209,754 | 1987 |
| Nadine Paiement | Vice-Chair of Scientific Advisory Board and Vice President of Research & Development - IntelGenx Corp | 215,087 | 1977 |
| André Godin | President & Chief Financial Officer | 359,578 | 1964 |
| Zenoz Nina Pourhassan | Vice President of Quality Operations of Subsidiary | 0 | N/A |
| Karen Kalayajian | Vice President of Finance & Administration | 0 | 1980 |
| Ingrid Zerbe | Corporate Secretary | 0 | 1954 |
| Stephen Kilmer | Investor Relations Officer | 0 | N/A |
Description
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
